Powder Or Dust Containing Patents (Class 424/46)
  • Patent number: 10219613
    Abstract: A method of magnetically induced removal of hair from a brush, wherein the method is comprised of the steps of applying a ferrofluid composition onto a portion of a user's hair; brushing the ferrofluid composition coated hair with a hair brush having a plurality of bristles; placing a magnetized hair brush base having a plurality of openings over the bristles such that the plurality of openings aligns with and interacts with the plurality of bristles such that substantially any of the user's hair that is located within the bristles is attracted towards the magnetized hair brush base; and removing the user's hair from the bristles.
    Type: Grant
    Filed: April 17, 2016
    Date of Patent: March 5, 2019
    Inventor: Vidhyasai Annem
  • Patent number: 10195149
    Abstract: The present invention relates to a continuous process for preparing microspheres and microspheres prepared thereby, and in particular, a process for preparing microspheres comprising steps of injecting a first emulsion and a second emulsion at the same time to form microspheres instantaneously, applying high pressure to the microspheres formed, and injecting the microspheres into an agitator, wherein the steps can be carried out continuously, and microspheres prepared thereby. When microspheres are prepared using the method of the present invention, scale variables, which have been the biggest disadvantage in existing preparation methods of microspheres, can be significantly reduced, drug encapsulation efficiency can be improved, and small and uniform particles can be obtained.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: February 5, 2019
    Assignee: CJ HEALTHCARE CORPORATION
    Inventors: Yi Mi Kim, Sun Kyung Lim, Mi Ran Park, Young Joon Park, Seung Hee Baek, Hyun Woo Shin
  • Patent number: 10188612
    Abstract: The invention provides microparticles for use in a pharmaceutical composition for pulmonary administration, each microparticle comprising a particle of an active substance having, on its surface, particles of a hydrophobic material suitable for delaying the dissolution of the active substance. The invention also provides a method for making the microparticles.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: January 29, 2019
    Assignee: Vectura Limited
    Inventors: John Nicholas Staniforth, Haggis Harris, David Alexander Vodden Morton, Robin Bannister
  • Patent number: 10188614
    Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: January 29, 2019
    Assignee: Nektar Therapeutics
    Inventors: Peter York, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
  • Patent number: 10172773
    Abstract: Disclosed is a method of reducing or avoiding staining in or on clothing caused by a cosmetic or dermatological preparation comprising one or more antiperspirant substances and/or of improving the ability of stains in or on clothing which are caused at least in part by said preparation to be washed out from the clothing. The method comprises including in the preparation one or more cationic surfactants.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: January 8, 2019
    Assignee: Beiersdorf AG
    Inventors: Michael Urban, Heike Miertsch, Stefan Biel, Sabine Kuehne, Stefan Bruening, Rolf Kawa
  • Patent number: 10159645
    Abstract: Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: December 25, 2018
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro Bonelli, Francesca Usberti, Enrico Zambelli
  • Patent number: 10119135
    Abstract: The present invention relates to the identification of microRNAs of the miR-148 family that are involved in the pathogenesis of chronic pulmonary diseases. The present invention relates to micro RNA of the miR-148 family selected from miR-148a, miR-148b and miR-152 for use in the diagnosis, prognosis, prevention and/or therapy of a chronic pulmonary disease. The present invention further relates to miR-148 inhibitors, pharmaceutical compositions comprising such inhibitors, their use in preventing and/or treating chronic pulmonary diseases, and methods for preventing and/or treating chronic pulmonary diseases. The present invention further relates to transgenic, non-human mammals and methods for identifying modulators of miR-148 and methods for diagnosis and/or prognosis of chronic pulmonary diseases.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: November 6, 2018
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Marcus Mall, Raman Agrawal, Martina Muckenthaler
  • Patent number: 10105300
    Abstract: Disclosed is cosmetic or dermatological preparation which is present as an aerosol spray and comprises one or more antiperspirant substances and one or more cationic surfactants.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: October 23, 2018
    Assignee: BEIERSDORF AG
    Inventors: Michael Urban, Heike Miertsch, Stefan Biel, Sabine Kuehne, Stefan Bruening, Rolf Kawa
  • Patent number: 10092512
    Abstract: The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: October 9, 2018
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Keith P. Johnston, Joshua Engstrom, Jasmine Rowe, Alan B. Watts, Robert O. Williams, III
  • Patent number: 10092557
    Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: October 9, 2018
    Assignee: Nortic Holdings Inc.
    Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru
  • Patent number: 10081060
    Abstract: A method of reducing silver(I) salts to silver nanoparticles employing a carbohydrate reductant in the presence of an inorganic base, a surfactant and optionally a polymer. The method is performed in an aqueous solution at a temperature up to 60° C. and for a duration of up to 40 minutes.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: September 25, 2018
    Assignee: King Abdulaziz University
    Inventors: Hassan Amroun Ewais, Iqbal Mohamed Ismail
  • Patent number: 10022323
    Abstract: The present invention concerns a method for making an inhaled pharmaceutical composition with improved powder handling properties comprising a stearate, a method of preparing such a composition, and the use of such a stearate in a composition when dispensed into a receptacle for use in a dry powder inhaler receptacle.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: July 17, 2018
    Assignee: VECTURA LIMITED
    Inventor: Matthew Green
  • Patent number: 10020807
    Abstract: Reduction/oxidation reagents have been found to be effective to chemically cure a sparse metal nanowire film into a fused metal nanostructured network through evidently a ripening type process. The resulting fused network can provide desirable low sheet resistances while maintaining good optical transparency. The transparent conductive films can be effectively applied as a single conductive ink or through sequential forming of a metal nanowire film with the subsequent addition of a fusing agent. The fused metal nanowire films can be effectively patterned, and the patterned films can be useful in devices, such as touch sensors.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: July 10, 2018
    Assignee: C3NANO INC.
    Inventors: Ajay Virkar, Xiqiang Yang, Ying-Syi Li, Dennis McKean, Melburne C. LeMieux
  • Patent number: 10004690
    Abstract: The present invention provides administrable microparticles in vivo through a medical conduit, a composition comprising the same, and a manufacturing method therefor. The microparticles of the present invention have an advantage that a clogging phenomenon does not occur for an endoscopic administration through a spray apparatus.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: June 26, 2018
    Assignee: UTAH-INHA DDS & ADVANCED THERAPEUTICS RESEARCH CENTER
    Inventors: Eunhye Lee, Keun Su Kim, Don Haeng Lee, Young Hwan Park
  • Patent number: 9855212
    Abstract: Embodiments of the invention relate generally to formulations comprising dimethylsulfoxide (DMSO) alone or in combination with methylsulfonylmethane (MSM), and one or more therapeutic agents, and uses of such formulations to treat infectious diseases. In several embodiments, such formulations are effective in treating drug-resistant infectious diseases, for example, drug-resistant tuberculosis.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: January 2, 2018
    Assignee: Abela Pharmaceuticals, Inc.
    Inventors: Colette Cozean, Rodney Benjamin, Anthony Keller, Jeff Varelman
  • Patent number: 9761771
    Abstract: The present application relates to a light-emitting film, a method of manufacturing the same, a lighting device and a display device. The present application may provide a light-emitting film capable of providing a lighting device having excellent color purity and efficiency and an excellent color characteristic. The characteristics of the light-emitting film of the present application may be stably and excellently maintained for a long time. The light-emitting film of the present application may be used for various uses including photovoltaic applications, an optical filter or an optical converter, as well as various lighting devices.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: September 12, 2017
    Assignee: LG CHEM, LTD.
    Inventors: Tae Gyun Kwon, Su Young Ryu, Moon Soo Park, Seong Min Lee
  • Patent number: 9750789
    Abstract: The present invention provides a method for treating a subject suffering from tuberculosis which comprises administering to the subject a composition comprising an amount of an inhibitor of a matrix metalloproteinase (MMP) in an amount effective to treat the subject, such that the therapeutic effect of said composition is different than the therapeutic effect attributable to the antibiotic properties of said composition. The present invention also provides a method for reducing or inhibiting destruction of lung extracellular matrix in a subject comprising administering to the subject at risk for such destruction a composition comprising an amount of an inhibitor of a matrix metalloproteinase (MMP) in an amount effective to reduce or inhibit destruction of lung extracellular matrix in the subject.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: September 5, 2017
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Jeanine D'armiento, Paul Elkington, Jon S. Friedland
  • Patent number: 9738780
    Abstract: Zwitterionic crosslinking agents, crosslinked zwitterionic hydrogels prepared from copolymerization of zwitterionic monomers with the zwitterionic crosslinking agent, methods for making crosslinked zwitterionic hydrogels, and devices that include and methods that use the crosslinked zwitterionic hydrogels.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: August 22, 2017
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Shaoyi Jiang, Hong Xue, Wei Yang, Louisa R. Carr
  • Patent number: 9724344
    Abstract: Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (Cmax) of at least about 0.25 ?g/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: August 8, 2017
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: James E. Hitt, True L. Rogers, Brian D. Scherzer, Ian B. Gillespie, Paula C. Garcia, Nicholas S. Beck, Christopher J. Tucker, Timothy J. Young, David A. Hayes, Robert O. Williams, III, Keith P. Johnston, Jason T. McConville, Jay I. Peters, Robert Talbert, David S. Burgess
  • Patent number: 9687536
    Abstract: Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: June 27, 2017
    Assignees: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Ryoichi Nagata, Shunji Haruta
  • Patent number: 9682038
    Abstract: Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy and for delivery by oral or nasal inhalation are provided, wherein said compositions additionally comprise particles of at least one additional active agent. Also provided are methods of preparation of the compositions and their use in medicine.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: June 20, 2017
    Assignee: Prosonix Limited
    Inventors: John Burns, Dipesh Parikh
  • Patent number: 9675629
    Abstract: The present invention relates to a pH-responsive metal-catechol derivative nanoparticle for drug delivery based on a mussel adhesive protein, particularly Fe(III)-DOPA nanoparticle, and a method for preparing the same. A nanoparticle for drug delivery according to the present invention is prepared using a pH responsive substance, catechol derivative-metal complex, particularly Fe(III)-DOPA complex, based on a mussel adhesive protein. Thereby, the present invention has excellent biocompatibility, is capable of easily and quickly penetrating into a target cell, and releases a loaded drug under acidic conditions, which enables to selectively deliver a drug to a specific disease having an acidic environment.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: June 13, 2017
    Assignee: Postech Academy-Industry Foundation
    Inventors: Hyung Joon Cha, Bum Jin Kim, Ho gyun Cheong
  • Patent number: 9643996
    Abstract: Processes and apparatuses for producing biologically-active, protein-rich microparticles under ambient conditions are disclosed. A protein solution is atomized and collected in a dehydration solvent that is being mixed. The resulting protein microparticles retain high specific activity without the need for large amounts of stabilizing excipients.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: May 9, 2017
    Assignee: Battelle Memorial Institute
    Inventors: Trevor Petrel, Craig Bartling, Lena Furci, Carrie Howland
  • Patent number: 9636350
    Abstract: The invention relates to a pharmaceutical composition of unit dose for inhalation by a human subject comprising a topical corticoid and a quinolone or fucidic acid, characterized in that the ratio of the weight of the topical corticoid to the weight of the quinolone or fucidic acid is between 0.02 and 20 and the amount of quinolone or of fucidic acid is less than 1 mg. This composition can be administered by nasal spray and is used for treating the upper and lower respiratory tract, in particular sinusitis and nasal polyps.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: May 2, 2017
    Inventor: Matthew Krayenbuhl
  • Patent number: 9617582
    Abstract: A system and method for detecting a biomarker in exhaled breath condensate nanodroplets comprises noninvasively collecting exhaled breath condensate nanodroplets of a subject, and analyzing said nanodroplets utilizing immuno-quantitative polymerase chain reaction to detect one or more target biomarkers.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: April 11, 2017
    Assignee: University of Maryland College Park
    Inventors: Donald K. Milton, Ian M. White
  • Patent number: 9610343
    Abstract: Viruses, and particularly genetically engineered, replication deficient viruses such as adenoviruses, poxviruses, MVA viruses, and baculoviruses which encode one or more antigens of interest, such as TB, malarial, and HIV antigens, are spray dried with a mannitol-cyclodextrin-trehalose-dextran (MCTD) to form a powder where the viability of the viruses are maintained at a suitable level for mass vaccinations after spray drying, and where the viability of the viruses are maintained at suitable level over a period of storage time, even in the presence of humidity.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: April 4, 2017
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Tom Han Jin, Eric I-Fu Tsao
  • Patent number: 9585835
    Abstract: The present invention provides dry powder formulations comprising nicotine, methods of using the same, and methods for making the same. The dry powder formulations may further comprise excipients, therapeutic agents, and flavor components. The dry powder formulations may be manufactured by dry processes and wet processes.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: March 7, 2017
    Assignee: Sansa Corporation (Barbados) Inc.
    Inventors: Alex Stenzler, Noe Zamel, Arthur Slutsky, Steven Ellis
  • Patent number: 9549936
    Abstract: Disclosed are a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same and a method for preparing the same. The inventive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribution in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon administration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: January 24, 2017
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Kyeong Soo Kim, Deokkyu Lee, Dong Ho Kim, Yong II Kim, Jae Hyun Park, Jong Soo Woo
  • Patent number: 9549925
    Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: January 24, 2017
    Assignee: INSMED INCORPORATED
    Inventor: Jeff Weers
  • Patent number: 9545382
    Abstract: A formulation for treating a patient with hepatocellular carcinoma is disclosed. The formulation comprises therapeutic agents in the form of nanoparticles containing one or more proteins or polysaccharides. The therapeutic agent is conjugated to an active targeting agent causing the formulation to preferentially segregate to the hepatocellular carcinoma tissue to release the therapeutic agents. Methods of treating hepatocellular carcinoma using the formulations are also disclosed.
    Type: Grant
    Filed: June 6, 2015
    Date of Patent: January 17, 2017
    Assignee: Amrita Vishwa Vidyapeetham University
    Inventors: Manzoor Koyakutty, Giridharan Loghanathan Malarvizhi, Shantikumar Nair
  • Patent number: 9539233
    Abstract: A method and composition for treatment of bacterial infections caused by gram negative or gram positive bacteria such as Staphylococcus aureus, Rhodococcus equi, Mycobacterium tuberculosis, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a formulation containing gallium (III), in a pharmaceutically acceptable salt or complex thereof.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: January 10, 2017
    Assignee: Aridis Pharmaceuticals Inc.
    Inventors: Satoshi Ohtake, Vu Truong-Le, David Lechuga-Ballesteros, Luisa Yee, Binh Pham, Russell Martin, Atul Saxena
  • Patent number: 9504742
    Abstract: Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: November 29, 2016
    Assignee: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Burton Dickey, Michael Tuvim, Scott Evans
  • Patent number: 9491946
    Abstract: Embodiments of the present disclosure, in one aspect, relate to compositions including a silver/silica nanocomposite, methods of making a silver/silica nanocomposite, methods of using a silver/silica nanocomposite, and the like.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: November 15, 2016
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Swadeshmukul Santra, Roseline Menezes
  • Patent number: 9433576
    Abstract: The invention relates to respirable dry particles that contain one or more divalent metal cations, such as calcium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: September 6, 2016
    Assignee: Pulmatrix, Inc.
    Inventors: Michael M. Lipp, Jean C. Sung
  • Patent number: 9415009
    Abstract: Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: August 16, 2016
    Assignee: Pearl Therapeutics, Inc.
    Inventors: Reinhard Vehring, Michael Steven Hartman, David Lechuga-Ballesteros, Adrian Edward Smith, Vidya B. Joshi, Sarvajna Kumar Dwivedi
  • Patent number: 9402918
    Abstract: A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, core-shell particle formulation configured to independently release therapeutic agents from the core and the shell. Moreover, the core-shell particle bearing therapeutic agents enables treatment against the diseases such as cancer, inflammatory and auto-immune diseases.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: August 2, 2016
    Assignee: Amrita Vishwa Vidyapeetham
    Inventors: Manzoor Koyakutty, Parwathy Chandran, Archana P. R., Shantikumar Nair
  • Patent number: 9394435
    Abstract: Zwitterionic crosslinking agents, crosslinked zwitterionic hydrogels prepared from copolymerization of zwitterionic monomers with the zwitterionic crosslinking agent, methods for making crosslinked zwitterionic hydrogels, and devices that include and methods that use the crosslinked zwitterionic hydrogels.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: July 19, 2016
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Shaoyi Jiang, Hong Xue, Wei Yang, Louisa R. Carr
  • Patent number: 9381152
    Abstract: The present invention provides an inhalation-type pharmaceutical composition for Parkinson's disease comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising levodopa, sinemet, atropine sulfate, scopolamine, dopamine agonist, bromocriptine mesylate, selegiline, carbidopa, entacapone, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can provide the convenience of taking medicine and removing harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. Therefore, the present invention can provide a treatment for Parkinson's disease that combines the convenience of taking the medicine while also having better curative effects on the user.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: July 5, 2016
    Inventor: Hsin-Yung Lin
  • Patent number: 9358318
    Abstract: The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: June 7, 2016
    Assignees: Ethicon, Inc., Omrix Biopharmaceutical, Inc.
    Inventors: Anne Jessica Gorman, Sanyog Manohar Pendharkar
  • Patent number: 9339453
    Abstract: The present invention provides for an oral serum made from natural ingredients that advantageously reduces oral bacteria. Further, toothpaste and oral rinse compositions are provided. A method for reducing oral bacteria using the oral serum of the present invention is additionally described herein.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: May 17, 2016
    Assignee: NOWSystem, Inc.
    Inventors: Janice Lou King, Dale Leland Winetroub
  • Patent number: 9339487
    Abstract: There is provided a dry powder pharmaceutical composition for inhalation useful for preventing and/or treating influenza virus infections contains as a medicinal component a compound represented by formula (I): and optionally a compound represented by formula (II): a pharmacologically acceptable salt thereof, or a hydrate thereof.
    Type: Grant
    Filed: December 24, 2009
    Date of Patent: May 17, 2016
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Makoto Miyajima, Shigeru Noda, Kazuhiro Inoue, Michiko Kumon, Katsuyasu Ishida, Hitoshi Ishizuka
  • Patent number: 9339459
    Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: May 17, 2016
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Peter York, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
  • Patent number: 9235814
    Abstract: Aspects of the present disclosure relate to management of evaluated rule data sets. Specifically, a unreduced evaluated rule data set may contain a number of items to be compared or analyzed according to a number of rules, and may also contain the results of such analysis. An illustrative reduced evaluated data set can include the results of evaluated rules. When utilized in conjunction with an item data set and a rule data set, the information contained within the unreduced evaluated rule data set may be maintained. The reduce memory requirements of the reduced evaluated rule data set may facilitate storage of the reduced evaluated rule data set in faster to access memory, or may facilitate distributed computation of the reduced evaluated rule data set.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: January 12, 2016
    Assignee: Amazon Technologies, Inc.
    Inventors: Jue Wang, Madhu M. Kurup, Jared S. Lundell, Thomas Robert Park
  • Patent number: 9233158
    Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: January 12, 2016
    Assignee: Pulmatrix, Inc.
    Inventors: Michael M. Lipp, Jean C. Sung, Robert W. Clarke, David L. Hava
  • Patent number: 9186817
    Abstract: A method for preparing tobramycin sulfate powder for injection is provided. The method includes steps of providing a sterile tobramycin sulfate solution; and aseptically spray drying the tobramycin sulfate solution to obtain the tobramycin sulfate powder.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: November 17, 2015
    Assignee: Sunny Pharmtech Inc.
    Inventors: Yen-Chih Lin, Yon-Lian Wu
  • Patent number: 9173895
    Abstract: The present invention relates to antisense oligonuclotides that modulate the expression of and/or function of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1), in particular, by targeting natural antisense polynucleotides of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MBTPS1.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: November 3, 2015
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Patent number: 9168278
    Abstract: The invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: October 27, 2015
    Assignee: GW Pharma Limited
    Inventors: Geoffrey William Guy, Roger Pertwee
  • Patent number: 9119897
    Abstract: A fibrin sealant comprises a mixture of first microparticles that comprise fibrinogen, second microparticles that comprise thrombin, and additive material. The additive material may be particulate, and may be, for instance, a biocompatible, water-absorbent, material, a biocompatible, water-swellable material, a biocompatible, water-insoluble material, a polysaccharide or silica.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: September 1, 2015
    Assignee: PROFIBRIX B.V.
    Inventors: Glen Patrick Martyn, Jacob Koopman
  • Patent number: 9072783
    Abstract: A method for the selection of pharmaceutically acceptable excipients that allow for the production of highly dispersible powders produced by spray drying.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: July 7, 2015
    Assignee: Aridis Pharmaceuticals
    Inventors: Satoshi Ohtake, Atul Saxena, Vu Truong-Le
  • Patent number: 9061352
    Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: June 23, 2015
    Assignee: Pulmatrix, Inc.
    Inventors: Michael M. Lipp, Jean C. Sung